Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma

cell growth esophageal squamous cell carcinoma (ESCC) keratin18 protein stability xanthohumol

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2020
Historique:
received: 12 02 2020
accepted: 24 04 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 9 6 2020
Statut: epublish

Résumé

Esophageal squamous cell carcinoma (ESCC) is a leading cause of cancer-related death worldwide. Xanthohumol is a prenylated flavonoid isolated from

Identifiants

pubmed: 32509787
doi: 10.3389/fcell.2020.00366
pmc: PMC7248302
doi:

Types de publication

Journal Article

Langues

eng

Pagination

366

Informations de copyright

Copyright © 2020 Yin, Song, Zhao, Liu, Kang, Lee, Kim, Zhang, Shim, Liu, Dong and Lee.

Références

Clin Cancer Res. 2012 Oct 1;18(19):5160-2
pubmed: 22912394
J Agric Food Chem. 2018 Sep 5;66(35):9248-9258
pubmed: 30113849
Biomed Pharmacother. 2018 Oct;106:1300-1306
pubmed: 30119200
Front Pharmacol. 2018 May 22;9:530
pubmed: 29872398
Biochim Biophys Acta Gen Subj. 2019 Nov;1863(11):129408
pubmed: 31386885
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Biosci Rep. 2019 Aug 13;39(8):
pubmed: 31345960
Oncotarget. 2016 Nov 8;7(45):73309-73322
pubmed: 27689336
Cancer Res. 2015 Apr 15;75(8):1560-6
pubmed: 25712343
Biochem Pharmacol. 2008 Mar 15;75(6):1262-71
pubmed: 18061144
Oncol Lett. 2018 Jan;15(1):908-916
pubmed: 29422966
Cancer Sci. 2018 Jan;109(1):132-140
pubmed: 29121426
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
J Agric Food Chem. 2019 Jul 31;67(30):8291-8302
pubmed: 31287692
Mol Cancer Ther. 2018 Jul;17(7):1540-1553
pubmed: 29695636
PLoS One. 2017 Dec 4;12(12):e0188842
pubmed: 29206234
Onco Targets Ther. 2019 Jan 29;12:883-896
pubmed: 30774375
Dis Markers. 2018 Feb 5;2018:5604702
pubmed: 29651326
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Molecules. 2015 Jan 07;20(1):754-79
pubmed: 25574819
Bio Protoc. 2016 Nov 20;6(22):
pubmed: 28184379
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817790
Gastrointest Tumors. 2016 Sep;3(1):3-16
pubmed: 27722152
Chin Clin Oncol. 2017 Oct;6(5):49
pubmed: 29129089
Onco Targets Ther. 2016 Nov 25;9:7235-7245
pubmed: 27932891
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50
pubmed: 22508028
Jpn J Clin Oncol. 2013 Jul;43(7):752-5
pubmed: 23625063
Oncol Rep. 2018 Dec;40(6):3213-3222
pubmed: 30272303
Medicines (Basel). 2017 Sep 14;4(3):
pubmed: 28930282
J Cell Biochem. 2018 Feb;119(2):2231-2239
pubmed: 28857247
Ann Gastroenterol Surg. 2019 Mar 01;3(3):269-275
pubmed: 31131355
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Adv Clin Chem. 2013;62:123-49
pubmed: 24772666
World J Gastrointest Oncol. 2019 Oct 15;11(10):830-841
pubmed: 31662822
Genet Mol Res. 2016 Aug 29;15(3):
pubmed: 27706656
Med Sci (Basel). 2019 Sep 26;7(10):
pubmed: 31561465
Int J Biol Sci. 2019 Sep 7;15(11):2497-2508
pubmed: 31595166
Int J Mol Med. 2002 Nov;10(5):641-6
pubmed: 12373308
Clin Gastroenterol Hepatol. 2019 Dec 4;:
pubmed: 31811953
Int Immunopharmacol. 2018 Aug;61:277-282
pubmed: 29906742
Sci Rep. 2017 Oct 26;7(1):14167
pubmed: 29074857
Int J Mol Sci. 2019 Mar 09;20(5):
pubmed: 30857300
Int J Cancer. 2019 Aug 15;145(4):1007-1019
pubmed: 30887517
Chin Clin Oncol. 2017 Oct;6(5):48
pubmed: 29129088
Transl Oncol. 2019 Feb;12(2):256-268
pubmed: 30439626
BMC Cancer. 2018 Nov 26;18(1):1170
pubmed: 30477458
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Shuying Yin (S)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.

Mengqiu Song (M)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.

Ran Zhao (R)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.

Xuejiao Liu (X)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.

Woo Kyu Kang (WK)

Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, United States.

Jeong Min Lee (JM)

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States.

Young Eun Kim (YE)

Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea.

Chengjuan Zhang (C)

The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, China.

Jung-Hyun Shim (JH)

Department of Pharmacy, College of Pharmacy, Mokpo National University, Mokpo-si, South Korea.

Kangdong Liu (K)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
College of Korean Medicine, Dongshin University, Naju, South Korea.

Zigang Dong (Z)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, United States.

Mee-Hyun Lee (MH)

Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
College of Korean Medicine, Dongshin University, Naju, South Korea.

Classifications MeSH